Stroke and thromboembolism in atrial fibrillation–systematic review of stroke risk factors and risk stratification schema–
Methods Studies were selected for review based on the published abstract content (or full
paper if no abstract was available) by 2 of the authors (RP and GYHL). They evaluated all …
paper if no abstract was available) by 2 of the authors (RP and GYHL). They evaluated all …
Major bleeding in patients with atrial fibrillation receiving vitamin K antagonists: a systematic review of randomized and observational studies
NS Roskell, M Samuel, H Noack, BU Monz - Europace, 2013 - academic.oup.com
Aims Clinical trials have shown that anticoagulation with vitamin K antagonists (VKAs), eg
warfarin, decreases the risk of stroke in patients with atrial fibrillation (AF); however …
warfarin, decreases the risk of stroke in patients with atrial fibrillation (AF); however …
Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With …
VY Reddy, S Möbius-Winkler, MA Miller… - Journal of the American …, 2013 - jacc.org
Objectives: The purpose of this study was to assess the safety and efficacy of left atrial
appendage (LAA) closure in nonvalvular atrial fibrillation (AF) patients ineligible for warfarin …
appendage (LAA) closure in nonvalvular atrial fibrillation (AF) patients ineligible for warfarin …
Incidence and prevalence of atrial fibrillation and associated mortality among Medicare beneficiaries: 1993–2007
JP Piccini, BG Hammill, MF Sinner… - … Quality and Outcomes, 2012 - Am Heart Assoc
Background—Atrial fibrillation (AF) is a common and costly problem among older persons.
The frequency of AF increases with age, but representative national data about incidence …
The frequency of AF increases with age, but representative national data about incidence …
Rates of hemorrhage during warfarin therapy for atrial fibrillation
T Gomes, MM Mamdani, AM Holbrook, JM Paterson… - Cmaj, 2013 - Can Med Assoc
Background: Although warfarin has been extensively studied in clinical trials, little is known
about rates of hemorrhage attributable to its use in routine clinical practice. Our objective …
about rates of hemorrhage attributable to its use in routine clinical practice. Our objective …
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective
SV Sorensen, AR Kansal, S Connolly… - Thrombosis and …, 2011 - thieme-connect.com
Oral dabigatran etexilate is indicated for the prevention of stroke and systemic embolism in
patients with atrial fibrillation (AF) in whom anticoagulation is appropriate. Based on the RE …
patients with atrial fibrillation (AF) in whom anticoagulation is appropriate. Based on the RE …
Validity of hospital discharge diagnosis codes for stroke: the Atherosclerosis Risk in Communities Study
Background and Purpose—Characterizing International Classification of Disease 9th
Revision, Clinical Modification (ICD-9-CM) code validity is essential given widespread use …
Revision, Clinical Modification (ICD-9-CM) code validity is essential given widespread use …
[HTML][HTML] Management of anticoagulation in patients with acute gastrointestinal bleeding
Acute gastrointestinal bleeding represents the most common adverse event associated with
the use of oral anticoagulant therapy. Due to increasing prescription of anticoagulants …
the use of oral anticoagulant therapy. Due to increasing prescription of anticoagulants …
Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with …
A Amin, S Deitelzweig, Y Jing, D Makenbaeva… - Journal of thrombosis …, 2014 - Springer
Warfarin's time-in-therapeutic range (TTR) is highly variable among patients with
nonvalvular atrial fibrillation (NVAF). The objective of this study was to estimate the impact of …
nonvalvular atrial fibrillation (NVAF). The objective of this study was to estimate the impact of …
Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and …
S Deitelzweig, A Amin, Y Jing… - Journal of medical …, 2012 - Taylor & Francis
Objective: The randomized clinical trials, RE-LY, ROCKET-AF, and ARISTOTLE,
demonstrate that the novel oral anticoagulants (NOACs) are effective options for stroke …
demonstrate that the novel oral anticoagulants (NOACs) are effective options for stroke …